On July 21, 2023, Quince Therapeutics, Inc. enters into a Stock Purchase Agreement to acquire Italian company EryDel S.p.A. Quince will issue up to 7,250,352 shares of its common stock to the EryDel Shareholders and assume EryDel’s $13M loan. After the acquisition, Quince will have approximately $87.6M in cash and short-term investments as of June 30, 2023. Additionally, one of EryDel's representatives, Luca Benatti, will join Quince's board, and Quince's Chief Medical Officer, Karen Smith, will leave the company effective September 1, 2023.